Cargando…

Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy

Detalles Bibliográficos
Autores principales:	Nitta, Masayuki, Kozono, David, Kennedy, Richard, Stommel, Jayne, Ng, Kimberly, Zinn, Pascal O., Kushwaha, Deepa, Kesari, Santosh, Furnari, Frank, Hoadley, Katherine A., Chin, Lynda, DePinho, Ronald A., Cavenee, Webster K., D'Andrea, Alan, Chen, Clark C.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084635/ http://dx.doi.org/10.1371/annotation/9b9cc4ae-ad56-464f-ab97-59f096b5c0eb

Ejemplares similares

Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy
por: Nitta, Masayuki, et al.
Publicado: (2010)

Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma
por: Li, Ming, et al.
Publicado: (2011)

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
por: Li, Jie, et al.
Publicado: (2014)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma
por: Read, Renee D., et al.
Publicado: (2009)

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
por: Gomez, German G., et al.
Publicado: (2013)

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell-signaling
por: Hu, Jingjing, et al.
Publicado: (2014)

Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma
por: Sturla, L-M, et al.
Publicado: (2011)

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
por: Wykosky, Jill, et al.
Publicado: (2011)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma
por: Ahmad, Fahim, et al.
Publicado: (2019)

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity
por: Zanca, Ciro, et al.
Publicado: (2017)

Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development
por: Wiedemeyer, Ruprecht, et al.
Publicado: (2008)

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?
por: Carrillo, Jose A., et al.
Publicado: (2019)

PARP-1 protein expression in glioblastoma multiforme
por: Galia, A., et al.
Publicado: (2012)

Radioiodinated PARP1 tracers for glioblastoma imaging
por: Salinas, Beatriz, et al.
Publicado: (2015)

Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer
por: Cron, Kyle R., et al.
Publicado: (2013)

A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma
por: Read, Renee D., et al.
Publicado: (2013)

WNT Signaling as a Therapeutic Target for Glioblastoma
por: Latour, Michael, et al.
Publicado: (2021)

Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis
por: Guo, Gao, et al.
Publicado: (2017)

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
por: Wu, Si-Han, et al.
Publicado: (2014)

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3
por: Benitez, Jorge A., et al.
Publicado: (2017)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3
por: Benitez, Jorge A., et al.
Publicado: (2018)

EL1 BUILDING A CAREER IN NEURO-ONCOLOGY RESEARCH
por: Cavenee, Webster K
Publicado: (2019)

SL2 ADVANCES IN MOLECULAR BIOLOGY AND GENETICS IN GLIOMA RESEARCH AND THERAPY
por: Cavenee, Webster K
Publicado: (2019)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

A feasibility study of the Nativis Voyager(®) device in patients with recurrent glioblastoma in Australia
por: Murphy, Michael, et al.
Publicado: (2019)

Targeting immunoliposomes to EGFR-positive glioblastoma
por: Kasenda, B., et al.
Publicado: (2022)

LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1
por: Patel, Deven, et al.
Publicado: (2019)

When less is more: Gaining power through gene rearrangement of amplified EGFR
por: Koga, Tomoyuki, et al.
Publicado: (2019)

Telomere Dysfunction as an Initiator of Inflammation: Clues to an Age-Old Mystery
por: Chakravarti, Deepavali, et al.
Publicado: (2021)

The Y of cancer sex differences
por: Li, Jiexi, et al.
Publicado: (2023)

IGFBP2 potentiates nuclear EGFR-STAT3 signaling
por: Chua, Corrine Yingxuan, et al.
Publicado: (2015)

EGFR associated expression profiles vary with breast tumor subtype
por: Hoadley, Katherine A, et al.
Publicado: (2007)

Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma
por: Kambach, Diane M., et al.
Publicado: (2017)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
por: Kang, Josephine, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sc2gpihkvv39nl31ldjsaa6p70